Amendment to Form 8-K
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
Date of Report (Date of earliest event reported)   August 22, 2005
     
Targeted Genetics Corporation
 
(Exact name of registrant as specified in its charter)
         
Washington   0-23930   91-1549568
(State or other jurisdiction
of incorporation)
  (Commission File
Number)
  (IRS Employer
Identification No.)
     
1100 Olive Way, Suite 100, Seattle, Washington   98101
(Address of principal executive offices)   (Zip Code)
     
Registrant’s telephone number, including area code   (206) 623-7612
     
Not Applicable
 
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 


 

Item 5.02.      Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
     On August 22, 2005, Targeted Genetics Corporation filed a current report on Form 8-K announcing, among other things, the appointment of David J. Poston as Acting Chief Financial Officer.
     On January 18, 2006, Targeted Genetics Corporation announced that Mr. Poston had been appointed Vice President, Finance, Chief Financial Officer and Treasurer. A press release announcing Mr. Poston’s permanent appointment is attached as Exhibit 99.1 to this amended current report and is incorporated herein by reference.
Item 9.01.     Financial Statements and Exhibits.
(c)   Exhibits
     
Exhibits:   Description of Document
99.1   Press Release dated January 18, 2006

2


 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  Targeted Genetics Corporation
 
 
 
 
  By:   /s/ H. Stewart Parker    
    H. Stewart Parker   
    President and Chief Executive Officer   
 
Dated: January 19, 2006

3


 

EXHIBIT INDEX
     
Exhibits:   Description of Document
99.1   Press Release dated January 18, 2006

4